Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phosphaden (adenosine phosphate) is an endogenous nucleotide that acts as a vasodilator, antiaggregant, and metabolic regulator. It is a key component of essential coenzymes involved in cellular oxidation-reduction processes and protein synthesis. Phosphaden is used to normalize porphyrin biosynthesis and improve microcirculation. Historically developed and manufactured in Belarus and Russia, it has been indicated for the treatment of acute intermittent porphyria, lead poisoning with polyneuritic syndrome, peripheral vascular diseases (such as obliterating endarteritis and thrombophlebitis), coronary heart disease, and diabetic retinopathy. It functions primarily as an agonist of adenosine receptors and an allosteric activator of AMP-activated protein kinase (AMPK).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on adenosine phosphate.